奥拉西坦胶囊治疗脑梗死后轻度认知功能障碍的价值体会

Value of Oxiracetam Capsule in the Treatment of Mild Cognitive Impairment after Cerebral Infarction

目的:观察分析奥拉西坦胶囊治疗脑梗死后认知障碍的临床疗效。方法:选择2017年6月—2019年5月我院收治的脑梗死恢复期认知功能障碍患者110例为本次的研究对象,将其随机分为两组:研究组(n=55)和对照组(n=55)。对照组患者采用常规的治疗方法,研究组患者加用奥拉西坦胶囊治疗。比较两组的临床总有效率,比较两组治疗前后蒙特利尔认知评估量表(MoCA)评分、简明精神症状检查表(MMSE)评分、巴塞尔(Barthel)指数和神经功能缺损程度(NIHSS)评分。结果:研究组患者的临床治疗总有效率明显高于对照组(89.09%VS 74.55%),差异有显著性(P<0.05)。两组患者治疗前的MoCA评分和MMSE评分之间比较,差异无显著性(P>0.05)。治疗后,研究组患者MoCA评分和MMSE评分均显著高于对照组,差异有显著性(P<0.05)。研究组患者治疗后Barthel指数高于对照组,NIHSS评分显著低于对照组,差异有显著性(P<0.05)。结论:奥拉西坦胶囊可以有效地改善脑梗死后认知功能障碍患者的临床症状,提高其生活能力,临床效果显著,在临床上值得进行广泛推广。

Objective:To observe and analyze the clinical effect of oxiracetam Capsule on cognitive impairment after cerebral infarction.Method:From June 2017 to may 2019,110 patients with cognitive impairment in the convalescent stage of cerebral infarction in our hospital were randomly divided into two groups:Study Group(n=55)and control group(n=55).The patients in the study group were treated with olacetam capsule.The total clinical effective rate of the two groups was compared,and the scores of Moca,MMSE,Barthel Index and NIHSS before and after treatment were compared.Result:The total effective rate of the study group was significantly higher than that of the control group(89.09%vs 74.55%)(P<0.05).There was no significant difference in MOCA score and MMSE score between the two groups before treatment(P>0.05).After treatment,the MOCA score and MMSE score in the study group were significantly higher than those in the control group(P<0.05).After treatment,the Barthel index of the study group was higher than that of the control group,and the NIHSS score was significantly lower than that of the control group(P<0.05).Conclusion:Oxiracetam capsule can effectively improve the clinical symptoms of patients with cognitive impairment after cerebral infarction,improve their living ability,clinical effect is significant,it is worth popularizing widely in clinical.